A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II/III

Latest Information Update: 14 Nov 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Fluoropyrimidine derivatives (Primary) ; GRANITE 001 (Primary) ; Ipilimumab (Primary) ; Oxaliplatin (Primary)
Indications Colorectal cancer
Focus Registrational; Therapeutic Use
Acronyms GRANITE-CRC-1L
Sponsors Gritstone bio

11 Nov 2024 According to a Gritstone bio media release, overall survival data remain immature, with mature data expected in 2H 2025
11 Nov 2024 Updated Phase 2 Interim results presented in the Gritstone bio Media Release.
30 Sep 2024 According to a Gritstone bio media release, company announced Interim Phase 2 Data for GRANITE Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com